{"id":"https://openalex.org/W4200310628","doi":"https://doi.org/10.1158/1535-7163.targ-21-p084","title":"Abstract P084: DCC-3116, a first-in-class selective inhibitor of ULK1/2 kinases and autophagy, synergizes with EGFR inhibitors osimertinib and afatinib in NSCLC preclinical models","display_name":"Abstract P084: DCC-3116, a first-in-class selective inhibitor of ULK1/2 kinases and autophagy, synergizes with EGFR inhibitors osimertinib and afatinib in NSCLC preclinical models","publication_year":2021,"publication_date":"2021-12-01","ids":{"openalex":"https://openalex.org/W4200310628","doi":"https://doi.org/10.1158/1535-7163.targ-21-p084"},"language":"en","primary_location":{"id":"doi:10.1158/1535-7163.targ-21-p084","doi":"https://doi.org/10.1158/1535-7163.targ-21-p084","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1535-7163.targ-21-p084","pdf_url":null,"source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5056952545","display_name":"Madhumita Jagannathan\u2010Bogdan","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210127537","display_name":"Deciphera Pharmaceuticals (United States)","ror":"https://ror.org/038hbfs18","country_code":"US","type":"company","lineage":["https://openalex.org/I4210127537"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Madhumita Bogdan","raw_affiliation_strings":["Deciphera Pharmaceuticals, Lawrence, KS"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Deciphera Pharmaceuticals, Lawrence, KS","institution_ids":["https://openalex.org/I4210127537"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089864580","display_name":"Mary Jane Timson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210127537","display_name":"Deciphera Pharmaceuticals (United States)","ror":"https://ror.org/038hbfs18","country_code":"US","type":"company","lineage":["https://openalex.org/I4210127537"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mary J. Timson","raw_affiliation_strings":["Deciphera Pharmaceuticals, Lawrence, KS"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Deciphera Pharmaceuticals, Lawrence, KS","institution_ids":["https://openalex.org/I4210127537"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5038385781","display_name":"Hikmat Al\u2010Hashimi","orcid":"https://orcid.org/0000-0001-5999-2874","observed_orcids":["https://orcid.org/0000-0001-5999-2874"]},"institutions":[{"id":"https://openalex.org/I4210127537","display_name":"Deciphera Pharmaceuticals (United States)","ror":"https://ror.org/038hbfs18","country_code":"US","type":"company","lineage":["https://openalex.org/I4210127537"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hikmat Al-Hashimi","raw_affiliation_strings":["Deciphera Pharmaceuticals, Lawrence, KS"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Deciphera Pharmaceuticals, Lawrence, KS","institution_ids":["https://openalex.org/I4210127537"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5064805833","display_name":"Zhan Yu","orcid":"https://orcid.org/0000-0002-6538-2199","observed_orcids":["https://orcid.org/0000-0002-6538-2199","https://orcid.org/0000-0002-8473-2799"]},"institutions":[{"id":"https://openalex.org/I4210127537","display_name":"Deciphera Pharmaceuticals (United States)","ror":"https://ror.org/038hbfs18","country_code":"US","type":"company","lineage":["https://openalex.org/I4210127537"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yu Zhan","raw_affiliation_strings":["Deciphera Pharmaceuticals, Lawrence, KS"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Deciphera Pharmaceuticals, Lawrence, KS","institution_ids":["https://openalex.org/I4210127537"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111867939","display_name":"Bryan D. Smith","orcid":"https://orcid.org/0009-0002-7666-7517","observed_orcids":["https://orcid.org/0009-0002-7666-7517"]},"institutions":[{"id":"https://openalex.org/I4210127537","display_name":"Deciphera Pharmaceuticals (United States)","ror":"https://ror.org/038hbfs18","country_code":"US","type":"company","lineage":["https://openalex.org/I4210127537"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Bryan D. Smith","raw_affiliation_strings":["Deciphera Pharmaceuticals, Lawrence, KS"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Deciphera Pharmaceuticals, Lawrence, KS","institution_ids":["https://openalex.org/I4210127537"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5103397917","display_name":"Daniel Lee Flynn","orcid":"https://orcid.org/0000-0002-3752-7370","observed_orcids":["https://orcid.org/0000-0002-3752-7370"]},"institutions":[{"id":"https://openalex.org/I4210127537","display_name":"Deciphera Pharmaceuticals (United States)","ror":"https://ror.org/038hbfs18","country_code":"US","type":"company","lineage":["https://openalex.org/I4210127537"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Daniel L. Flynn","raw_affiliation_strings":["Deciphera Pharmaceuticals, Lawrence, KS"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Deciphera Pharmaceuticals, Lawrence, KS","institution_ids":["https://openalex.org/I4210127537"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I4210127537"],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":8,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"20","issue":"12_Supplement","first_page":"P084","last_page":"P084"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.9639000296592712,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.9639000296592712,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10587","display_name":"Autophagy in Disease and Therapy","score":0.03460000082850456,"subfield":{"id":"https://openalex.org/subfields/1307","display_name":"Cell Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/autophagy-inhibition","display_name":"autophagy inhibition","score":0.9490000009536743},{"id":"https://openalex.org/keywords/egfr-inhibitors","display_name":"EGFR inhibitors","score":0.7450000047683716},{"id":"https://openalex.org/keywords/osimertinib","display_name":"osimertinib","score":0.9739999771118164},{"id":"https://openalex.org/keywords/afatinib","display_name":"afatinib","score":1.0},{"id":"https://openalex.org/keywords/non-small-cell-lung-cancer","display_name":"non-small cell lung cancer","score":0.9120000004768372},{"id":"https://openalex.org/keywords/egfr-mutation","display_name":"EGFR mutation","score":0.753000020980835},{"id":"https://openalex.org/keywords/drug-resistance","display_name":"drug resistance","score":0.8500000238418579},{"id":"https://openalex.org/keywords/autophagy","display_name":"autophagy","score":0.5180000066757202},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.6539999842643738},{"id":"https://openalex.org/keywords/nci-h1975","display_name":"NCI-H1975","score":0.8159999847412109},{"id":"https://openalex.org/keywords/egfr-t790m-mutation","display_name":"T790M mutation","score":0.7059999704360962},{"id":"https://openalex.org/keywords/exon-19-deletion","display_name":"exon 19 deletion","score":0.6420000195503235}],"concepts":[{"id":"https://openalex.org/C2780586478","wikidata":"https://www.wikidata.org/wiki/Q4688818","display_name":"Afatinib","level":5,"score":0.9284248352050781},{"id":"https://openalex.org/C2777626846","wikidata":"https://www.wikidata.org/wiki/Q21506464","display_name":"Osimertinib","level":5,"score":0.7150800228118896},{"id":"https://openalex.org/C203522944","wikidata":"https://www.wikidata.org/wiki/Q288322","display_name":"Autophagy","level":3,"score":0.712945282459259},{"id":"https://openalex.org/C2778087573","wikidata":"https://www.wikidata.org/wiki/Q418369","display_name":"Erlotinib","level":4,"score":0.661639392375946},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5976608395576477},{"id":"https://openalex.org/C2777930144","wikidata":"https://www.wikidata.org/wiki/Q25100112","display_name":"T790M","level":5,"score":0.5674008727073669},{"id":"https://openalex.org/C184235292","wikidata":"https://www.wikidata.org/wiki/Q421851","display_name":"Kinase","level":2,"score":0.5286149382591248},{"id":"https://openalex.org/C2780580887","wikidata":"https://www.wikidata.org/wiki/Q417824","display_name":"Gefitinib","level":4,"score":0.4767090678215027},{"id":"https://openalex.org/C2777506169","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"EGFR inhibitors","level":4,"score":0.4596644639968872},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.43514564633369446},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.4107131361961365},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.33686771988868713},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.33247125148773193},{"id":"https://openalex.org/C2779438470","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"Epidermal growth factor receptor","level":3,"score":0.2951497733592987},{"id":"https://openalex.org/C95444343","wikidata":"https://www.wikidata.org/wiki/Q7141","display_name":"Cell biology","level":1,"score":0.15844997763633728},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.11346951127052307},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.10651010274887085},{"id":"https://openalex.org/C190283241","wikidata":"https://www.wikidata.org/wiki/Q14599311","display_name":"Apoptosis","level":2,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1535-7163.targ-21-p084","doi":"https://doi.org/10.1158/1535-7163.targ-21-p084","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1535-7163.targ-21-p084","pdf_url":null,"source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9789000153541565,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W7166697010","https://openalex.org/W2072098186","https://openalex.org/W4362541428","https://openalex.org/W2946539744","https://openalex.org/W2963654362","https://openalex.org/W2027216014","https://openalex.org/W2201010417","https://openalex.org/W4226078855","https://openalex.org/W3030890914","https://openalex.org/W2237248451"],"abstract_inverted_index":{"Abstract":[0],"Background:":[1],"Activating":[2],"mutations":[3,49,134],"in":[4,9,172,194,215,228,256,317,325,330,342,351,406,412,418,466],"EGFR":[5,24,65,89,96,108,133,180,277,399,461],"have":[6,27,76],"been":[7,28],"reported":[8],"~30%":[10],"of":[11,21,40,106,142,234,247,265,270,274,301,306,335,393,454,473],"patients":[12,81,419],"with":[13,95,110,132,267,283,303,337,398,420,424,460],"non-small":[14],"cell":[15,218,281],"lung":[16],"cancer":[17,43,130,407],"(NSCLC).":[18],"Three":[19],"generations":[20],"small":[22],"molecule":[23],"kinase":[25],"inhibitors":[26,66,97,400,462],"approved":[29],"by":[30,226,320],"the":[31,115,165,193,200,216,235,275,315,352,391,394,474],"FDA":[32],"to":[33,47,61,117,329,389],"treat":[34],"these":[35,321,324],"patients,":[36],"however,":[37],"multiple":[38],"mechanisms":[39],"resistance":[41,101,182],"cause":[42,62],"progression.":[44],"In":[45],"addition":[46],"drug-resistant":[48],"that":[50,177],"arise":[51],"and":[52,70,119,122,127,150,155,207,243,252,262,297,309,313,404,457,464,482],"re-activate":[53],"EGFR,":[54],"other":[55],"signaling":[56],"pathways":[57],"can":[58],"be":[59],"activated":[60,209],"resistance.":[63,84],"Although":[64],"such":[67,401],"as":[68,98,224,402],"osimertinib":[69,284,296,338,359,369,403,463],"afatinib":[71,208,286,298,340,365,376,405,465],"(also":[72],"a":[73,99,104,231,386,413,425,450],"pan-ErbB":[74],"inhibitor)":[75],"demonstrated":[77],"clear":[78],"clinical":[79,416],"benefits,":[80],"inevitably":[82],"develop":[83],"Herein":[85],"we":[86],"demonstrate":[87],"mutant":[88],"NSCLCs":[90],"activate":[91],"autophagy":[92,112,210,288],"upon":[93],"treatment":[94],"drug":[100],"mechanism.":[102],"Therefore,":[103],"combination":[105,334,363,370,377,392],"an":[107,111,179,240],"inhibitor":[109,113,246,396,453],"has":[114],"potential":[116],"deepen":[118],"prolong":[120],"responses":[121,346],"improve":[123],"patient":[124],"outcomes.":[125],"Materials":[126],"Methods:":[128],"Human":[129],"cells":[131,176],"were":[135,184,197],"cultured":[136],"using":[137,164,199],"recommended":[138],"complete":[139],"medium.":[140],"Inhibition":[141],"ULK1/2":[143,455],"was":[144,162],"measured":[145,163,225],"through":[146],"standard":[147],"biochemical":[148],"assays":[149],"cellular":[151,232,257],"readouts":[152],"including":[153],"NanoBRET":[154],"ELISA-based":[156],"ATG13":[157,266,302],"phosphorylation":[158,264,300],"assays.":[159],"Autophagosome":[160],"formation":[161],"CytoID":[166],"assay":[167],"(Enzo":[168],"Life":[169],"Sciences).":[170],"For":[171],"vivo":[173,195,331],"studies,":[174],"NCI-H1975":[175,276,353],"harbor":[178],"T790M":[181],"mutation":[183,430],"inoculated":[185],"into":[186],"BALB/c":[187],"nude":[188],"mice.":[189],"Statistical":[190],"analyses":[191],"for":[192],"studies":[196],"performed":[198],"Student\u2019s":[201],"t-test.":[202],"Results:":[203],"Erlotinib,":[204],"gefitinib,":[205],"osimertinib,":[206],"3\u20134-fold":[211],"over":[212,290],"basal":[213,263,291],"levels":[214],"HCC827":[217],"line":[219,282],"(EGFR":[220],"exon":[221],"19":[222],"deletion)":[223],"increases":[227],"phosphorylated":[229],"ATG13,":[230],"substrate":[233],"autophagy-initiating":[236],"kinases":[237,456],"ULK1/2.":[238],"DCC-3116,":[239,449],"investigational":[241],"potent":[242],"selective":[244,452],"dual":[245],"ULK1":[248],"(IC50":[249],"6":[250],"nM)":[251,255],"ULK2":[253],"(9":[254],"assays,":[258],"inhibited":[259,295,314],"both":[260],"EGFR-induced":[261],"IC50":[268,304],"values":[269,305],"61\u201366":[271],"nM.":[272],"Treatment":[273],"mutated":[278],"(L858R/T790M)":[279],"NSCLC":[280,354,467],"or":[285,339,428],"induced":[287,299,319],"3-fold":[289],"levels.":[292],"DCC-3116":[293,336,397,409],"potently":[294],"91":[307],"nM":[308],"71":[310],"nM,":[311],"respectively,":[312],"increase":[316],"autophagosomes":[318],"agents.":[322],"Importantly,":[323],"vitro":[326],"effects":[327],"translated":[328],"efficacy.":[332],"The":[333],"resulted":[341],"significantly":[343],"greater":[344],"tumor":[345],"than":[347],"single":[348],"agent":[349],"treatments":[350],"xenograft":[355],"model":[356],"(combination":[357],"vs.":[358,364,378],"p":[360,366,373,380],"=":[361,367],"0.0005;":[362],"0.0001;":[368,375],"vs":[371],"vehicle":[372,379],"<":[374,381],"0.0001).":[382],"These":[383],"data":[384],"provide":[385],"strong":[387],"rationale":[388],"study":[390],"ULK":[395],"patients.":[408],"is":[410],"currently":[411],"Phase":[414],"1":[415],"trial":[417],"advanced":[421],"solid":[422],"tumors":[423],"documented":[426],"RAS":[427],"RAF":[429],"(NCT04892017).":[431],"Citation":[432],"Format:":[433],"Madhumita":[434],"Bogdan,":[435],"Mary":[436],"J.":[437],"Timson,":[438],"Hikmat":[439],"Al-Hashimi,":[440],"Yu":[441],"Zhan,":[442],"Bryan":[443],"D.":[444],"Smith,":[445],"Daniel":[446],"L.":[447],"Flynn.":[448],"first-in-class":[451],"autophagy,":[458],"synergizes":[459],"preclinical":[468],"models":[469],"[abstract].":[470],"In:":[471],"Proceedings":[472],"AACR-NCI-EORTC":[475],"Virtual":[476],"International":[477],"Conference":[478],"on":[479],"Molecular":[480],"Targets":[481],"Cancer":[483,492],"Therapeutics;":[484],"2021":[485],"Oct":[486],"7-10.":[487],"Philadelphia":[488],"(PA):":[489],"AACR;":[490],"Mol":[491],"Ther":[493],"2021;20(12":[494],"Suppl):Abstract":[495],"nr":[496],"P084.":[497]},"counts_by_year":[{"year":2026,"cited_by_count":4},{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":2}],"updated_date":"2026-11-07T11:25:07.637180","created_date":"2021-12-31T00:00:00"}